Human soluble tumor necrosis factor-related apoptosis inducing ligand,sTRAIL ELISA KIT

Instructions
Code CSB-E04750h
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name tumor necrosis factor (ligand) superfamily, member 10
Alternative Names Apo 2 ligand ELISA Kit; APO 2L ELISA Kit; Apo-2 ligand ELISA Kit; Apo-2L ELISA Kit; APO2L ELISA Kit; CD253 ELISA Kit; CD253 antigen ELISA Kit; Chemokine tumor necrosis factor ligand superfamily member 10 ELISA Kit; Protein TRAIL ELISA Kit; TL2 ELISA Kit; TNF Related Apoptosis Inducing Ligand ELISA Kit; TNF related apoptosis inducing ligand TRAIL ELISA Kit; TNF-related apoptosis-inducing ligand ELISA Kit; TNF10_HUMAN ELISA Kit; TNFSF10 ELISA Kit; TRAIL ELISA Kit; Tumor necrosis factor (ligand) family member 10 ELISA Kit; Tumor Necrosis Factor (ligand) Superfamily Member 10 ELISA Kit; Tumor necrosis factor apoptosis inducing ligand splice variant delta ELISA Kit; Tumor necrosis factor ligand superfamily member 10 ELISA Kit
Abbreviation TNFSF10
Uniprot No. P50591
Species Homo sapiens (Human)
Sample Types serum, plasma, cell culture supernates, urine, cerebrospinal fluid(CSF)
Detection Range 31.25 pg/mL-2000 pg/mL
Sensitivity 7.81 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cell Biology
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human sTRAIL in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 103
Range % 99-110
1:2 Average % 96
Range % 92-100
1:4 Average % 90
Range % 85-94
1:8 Average % 92
Range % 88-96
Recovery
The recovery of human sTRAIL spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 88 84-92
EDTA plasma (n=4) 95 90-100
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected
2000 2.158 2.257 2.208 2.040
1000 1.621 1.720 1.671 1.503
500 1.103 1.068 1.086 0.918
250 0.719 0.703 0.711 0.543
125 0.462 0.485 0.474 0.306
62.5 0.337 0.319 0.328 0.160
31.25 0.230 0.241 0.236 0.068
0 0.164 0.172 0.168  
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Target Data

Function Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG
Gene References into Functions
  1. TRAIL protects against insulin resistance, NAFLD and vascular inflammation. Increasing TRAIL levels may be an attractive therapeutic strategy, to reduce features of diabetes, as well as liver and vascular injury, so commonly observed in individuals with NAFLD. PMID: 28507343
  2. data strongly suggest that XIAP-mediated inhibition of final caspase-3 processing is the last and major hurdle in TRAIL-induced apoptosis in NCI-H460 cells, which can be overcome by Smac in a Bcl-2 level dependent manner. PMID: 29927992
  3. Patients harboring the homozygous AA genotype of TRAIL SNPs rs1131568 and rs1131579 and the TT genotype of the TRAIL SNP rs1131580 had lower overall survival and higher rates of extrahepatic recurrence (EHR) than patients harboring the wild type or heterozygous genotypes. PMID: 30051596
  4. TRAIL synergistically sensitized irradiation-induced apoptosis in glioblastoma stem-like cells by increasing DR5 expression and decreasing cFLIP expression. PMID: 29777390
  5. Serum TRAIL concentrations are significantly reduced in patients with early preeclampsia. PMID: 29674187
  6. The combination treatment with ILz:rhTRAIL and bortezomib was able to induce cell death in both TRAIL-susceptible and TRAIL-resistant cancer cells through the intracellular TRAIL signaling pathway. The efficiency of cell death was dependent on the properties of TRAIL under the environment provided by bortezomib. The combination treatment-induced cell death was not regulated by bortezomib-induced ER stress response or by a PMID: 29661248
  7. A significant relationship was found between TRAIL polymorphisms and the susceptibility and severity of intervertebral disc degeneration in Han Chinese. PMID: 29284457
  8. High expression level of Galectin-3 and low expression level of TRAIL were found to be positively correlated with the shorter median survival time and overall survival time. PMID: 28925481
  9. Genes related to the extrinsic pathway of apoptosis including a receptor for TRAIL. PMID: 30061204
  10. Nelfinavir induces ER stress in renal cancer cells and sensitizes them to TRAIL. PMID: 30061216
  11. DR5-Cbl-b/c-Cbl-TRAF2 complex inhibited TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells. PMID: 28972304
  12. We found that the combination of alpha-mangostin with TRAIL induced apoptosis of SAS cells through the mitochondrial pathway via activation of caspase-9 and -3/7, following release of cytochrome c. This apoptosis was induced by S/G2/M-phase arrest. Immunopositivity for c-Myc was observed in the cytoplasm of tumor cells in 16 (40%) of the 40 cases of human oral squamous cell carcinoma (HOSCC). PMID: 29039600
  13. this study characterized in juvenile systemic lupus erythematosus a distinct profile from adult SLE that comprises increased sFas, sTRAIL, and reduced sFasL, notably in patients with active disease and with nephritis. PMID: 28378099
  14. Notch1 activation also suppressed A549 cell apoptosis by inhibiting the PI3K/pAkt pathway and activating the caspase-3 pathway in cooperation with TRAIL. Combining Notch1 signal with TRAIL inhibited PI3K, phosphorylated Akt and phosphorylated STAT3 expressions. PMID: 28718726
  15. we show that executioner caspase activation of the apoptotic nuclease CAD/DFF40 is essential for TRAIL-induced mutations in surviving cells. As exposure to chemotherapy drugs also activates apoptotic caspases and presumably CAD, we hypothesized that these pathways may also contribute to the mutagenesis induced by conventional chemotherapy drugs, perhaps augmenting the mutations that arise from direct DNA damage PMID: 28981092
  16. Cultured HCN-2 neurons were incubated at different times with GITRL and/or TRAIL, and thereafter nucleic acid and protein expression were measured. HCN-2 cells do not express GITRL mRNA, but the latter is induced after treatment with TRAIL. Cells did not express the GITRL receptor GITR mRNA, neither in control cultures, nor after treatment with TRAIL. TRAIL, when associated to GITRL, exerted additive toxic effects. PMID: 28524007
  17. DR5 has a dual role in death and survival signaling, which results in TRAIL resistance in cancer cells. PMID: 29048428
  18. Dynamin isoforms differentially regulate the endocytosis and apoptotic signaling downstream of TRAIL-death receptor (TRAIL-DR) complexes in cancer cells. TRAIL stimulation activates ryanodine receptor-mediated calcium release from endoplasmic reticulum stores, leading to calcineurin-mediated dephosphorylation and activation of Dyn1, TRAIL-DR endocytosis, and increased resistance to TRAIL-induced apoptosis. PMID: 28049841
  19. These results suggest that the FasL -844T>C single nucleotide polymorphism is implicated in the susceptibility to hepatitis C virus in Egyptian patients and firstly report the involvement of TRAIL gene polymorphism in the risk of the disease. PMID: 28587866
  20. ONC201 has potent antiproliferative and proapoptotic effects in a broad range of breast cancer subtypes, through TRAIL-dependent and TRAIL-independent mechanisms.The small-molecule ONC201 induces expression of TRAIL and its receptor DR5. ONC201 has entered clinical trials in advanced cancers. Here, we show that ONC201 is efficacious against both triple-negative breast cancers (TNBC) and non-TNBC cells PMID: 28424227
  21. our data suggest that nanoparticle-engineered TRAIL-expressing human adipose-derived stem cells exhibit the therapeutically relevant behavior of "seek-and-destroy" tumortropic migration and could be a promising therapeutic approach to improve the treatment outcomes of patients with malignant brain tumors. PMID: 27849590
  22. CaP@LDL-mediated STAT3-decoy ODN delivery might be a promising new strategy for reversing TRAIL resistance in hepatocellular carcinoma therapy. PMID: 29158840
  23. RA/poly(I:C) combination synergizes to induce a bioactive autocrine/paracrine loop of type-I Interferons (IFNs) which is ultimately responsible for TRAIL and TRAIL-R1/2 expression upregulation, while inhibition of TRAIL-R3/4 expression is type-I IFN-independent. PMID: 28409399
  24. our results demonstrated that nanovectorization of TRAIL with BNNTs enhanced its binding to both DR4 and DR5 receptors at 37 degrees C. Our novel nanovector could potentially be used for delivering TRAIL to cells for cancer treatment PMID: 28120533
  25. In primary hyperparathyroidism, hyperplasias demonstrated the highest expression of TRAIL and Fas, whereas in adenomas it was increased compared to normal tissue, but lower than in hyperplasias. PMID: 27763797
  26. Long-term toxicity test in cynomolgus monkeys did not cause rAAV2-sTRAIL95-281-related toxic and side effects, except that anti-AAV and anti-sTRAIL antibodies were generated. In conclusion, these data demonstrated that administration of rAAV2-sTRAIL95-281 in mice and in cynomolgus monkeys is safe without obvious toxic and side effects to the animals, and throw light on pharmacokinetics and safety in human clinical trials PMID: 28429751
  27. we found that plumbagin could enhance TRAIL-induced apoptosis in Kasumi-1 cells, and the mechanisms include ROS-mediated upregulation of DR5 expression, caspase-8 activation and inhibition of cFLIP expression PMID: 28498435
  28. None of these crude extracts exhibited cytotoxic effect on normal mouse embryonic fibroblasts (MEF), with the exception of EGY34. Analysis of the signaling pathways underlying the sensitization of MDA-MB-231 cells to TRAIL-induced apoptosis, by western blotting, revealed that all crude extracts facilitated initiator caspase8/-10 activation upon TRAIL stimulation PMID: 28440502
  29. Report a novel mechanism for the TRAIL-induced apoptosis of TrkAIII expressing NB cells that depends upon SHP/Src-mediated crosstalk between the TRAIL-receptor signaling pathway and TrkAIII. PMID: 27821809
  30. our findings identify a key role for c-Myc in TRAIL deregulation and as a biomarker of the anticancer action of HDACi in acute myeloid leukemia . PMID: 27358484
  31. Apoptosis induced by TRAIL is preferentially induced by TRAIL-R1 pathway in breast/lung tumor cells. PMID: 28039489
  32. These effects of metformin were accompanied by robust reductions in the protein levels of XIAP, a negative regulator of TRAIL-induced apoptosis. Silencing XIAP in TNBC cells mimicked the TRAIL-sensitizing effects of metformin. Metformin also enhanced the antitumor effects of TRAIL in a metastatic murine TNBC model PMID: 28324269
  33. siRNA silencing of CHOP significantly reduced cyproterone acetate-induced DR5 up-regulation and TRAIL sensitivity in prostate cancer cells. Our study shows a novel effect of cyproterone acetate on apoptosis pathways in prostate cancer cells and raises the possibility that a combination of TRAIL with cyproterone acetate could be a promising strategy for treating castration-resistant prostate cancer. PMID: 28270124
  34. TRAIL-armed exosomes can induce apoptosis in cancer cells. PMID: 26944067
  35. TRAIL expression in CTLs was negatively correlated with the expression of perforin and granzyme B, and negatively correlated with CTLs apoptosis in severe aplastic anemia patients. PMID: 28631177
  36. results provide convincing evidence that employing TRAIL combined with cisplatin/LA-12 could contribute to more effective killing of prostate cancer cells compared to the individual action of the drugs, and offer new mechanistic insights into their cooperative anticancer action PMID: 29182622
  37. UMI-77 enhances TRAIL-induced apoptosis by unsequestering Bim and Bak, which provides a novel therapeutic strategy for the treatment of gliomas. PMID: 28337703
  38. These results reveal KDM4A as a key epigenetic silencer of TRAIL and DR5 in tumors. PMID: 27612013
  39. Low Trail expression is associated with esophageal cancer. PMID: 29055676
  40. Results show that TNF-Related Apoptosis Inducing Ligand (TRAIL/TNFSF10) mRNA level correlates with T4 effector-memory lymphocytes (T4EM) lymphocytes radiosensitivity. PMID: 26982083
  41. Imbalance of the apoptosis pathway, with dysregulation of p73 and TRAIL, seems to play a role in the oncogenesis of odontogenic tumors PMID: 28025428
  42. hepatitis B virus (HBV) X protein (HBx) restricts TNFSF10 receptor signaling via macroautophagy/autophagy-mediated degradation of TNFRSF10B/DR5, a TNFSF10 death receptor. PMID: 27740879
  43. Findings suggest that loss of function of the human TRAIL promoter due to the SNP mutation leads to reduced expression and impaired inducibility of TRAIL, with the consequence of enhanced growth and migration of tumor cells, ultimately resulting in the progression of the hepatocellular carcinoma. PMID: 27580702
  44. these data show increased TRAIL mRNA expression in the airways and parenchyma in chronic obstructive pulmonary disease PMID: 26555706
  45. TRAIL expression is associated with thyroid hormone levels in vivo and TRAIL expression in peripheral blood mononuclear cells is stimulated by thyroid hormones in vitro. PMID: 28551332
  46. Antagonistic antibodies against the death receptors demonstrated that Apo2L/TRAIL mediated its apoptotic signals through activation of the TRAIL-R2 in PTHrP expressing breast cancer cells PMID: 23822995
  47. Co-treatment of carboplatin and autophagy inhibitor chloroquine increased lung tissue infiltration by CD4(+), FoxP3(+) lymphocytes and antigen-specific immune activation. Subsequent ex vivo experiments showed the activation of carboplatin related TRAIL-dependent apoptosis through caspase 8 and a synergistic role of miR-155 in lung tissue infiltration by CD4(+), and FoxP3(+) lymphocytes. PMID: 27692344
  48. Caspase-8 can serve in two distinct roles in response to TRAIL receptor engagement, as a scaffold for assembly of a Caspase-8-FADD-RIPK1 "FADDosome" complex, leading to NFkappaB-dependent inflammation, or as a protease that promotes apoptosis. PMID: 28212752
  49. Endogenous TRAIL/TRAIL-R-mediated CCL2 secretion promotes accumulation of tumor-supportive immune cells in the cancer microenvironment. PMID: 28212753
  50. BAY61-3606 sensitizes colon cancer cells to TRAIL-induced apoptosis by up-regulating DR4 expression in p53-dependent manner and inhibiting NF-kappaB activity. PMID: 27721019
  51. High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer cells and xenograft tumors. PMID: 27725224
  52. results suggest that miR-223 increases the sensitivity of TNBCSCs to TRAIL-induced apoptosis by targeting HAX-1 PMID: 27618431
  53. the impact of TRAIL on adipogenesis, was examined. PMID: 27735943
  54. The results suggested that miR-138 regulates the interferon-stimulated gene 15 expression by directly targeting the 3' untranslated region of interferon-stimulated gene 15 and modulates the sensitivity to TRAIL-induced apoptosis. PMID: 28639887
  55. these results demonstrate that high HOTAIR levels increase the resistance of pancreatic cancer cells to TRAIL-induced apoptosis via epigenetic regulation of DR5 expression. PMID: 28476883
  56. miR-661 overexpression sensitized tumors to TRAIL or STS induced apoptosis in a xenograft mouse model, and these effects were attenuated by co-expression of CYC1. PMID: 28391262
  57. sorafenib overcomes TRAIL resistance in renal cell carcinoma by a mechanism that does not rely on Mcl-1 down-regulation but involves ROS accumulation and increased activation of caspase-8 PMID: 28154184
  58. Our data showed that Ad/TRAIL-E1 induced TRAIL-mediated apoptosis in gastric cancer cell lines, but not in the normal cell lines. In addition, Ad/TRAIL-E1 significantly inhibited peritoneal metastasis and prolonged the survival of mice without treatment-related toxicity PMID: 28075429
  59. results indicate that E2 inhibits VSMCs proliferation and migration by downregulation of TRAIL expression via suppression of NF-kappaB pathway. PMID: 26878683
  60. TRAIL might promote hypoxic A549 cell radiosensitivity and induce apoptosis depending on DR5 to caspase-3 pathways. PMID: 27878298
  61. Combined triple actions of the TRAIL, the IAPs inhibitor, AT406, and the c-FLIP expression inhibitor, rocaglamide (ART), markedly improve TRAIL-induced apoptotic effects in most solid cancer cell lines through the activation of an extrinsic apoptosis pathway PMID: 27210546
  62. We demonstrate that PBOX-15 can enhance TRAIL-induced apoptosis by upregulation of DR5, reduction of cellular mitochondrial potential, activation of the caspase cascade and downregulation of PI3K/Akt, c-FLIP, Mcl-1 and IAP survival pathways PMID: 27176505
  63. TRAIL may provide a new strategy for CD133hi CSCs of HCC-targeted therapies. PMID: 28281970
  64. The nanovectorization of TRAIL enhanced its binding to both DR4 and DR5 receptors at 37 degrees C and could potentially sensitized cancer cells to TRAIL induced apoptosis through simultaneous activation of DR4 and DR5 as described in this paper for the non-small lung carcinoma cell line (H1703), the two hepatocarcinoma cell lines (SK-Hep1, HUH) and the colon carcinoma cell line (HCT116WT). PMID: 27750195
  65. Manipulating the expression of both miR-222 and miR-25 influenced diverse gene expression changes in thyroid cells. Increased expression of miR-25 reduced MEK4 and TRAIL protein expression, and cell adhesion and apoptosis are important aspects of miR-25 functioning in thyroid cells. PMID: 27353001
  66. we found that CQ decreased the expression of Cbl, an E3 ligase of DR5, and knock-down of Cbl markedly enhanced DR5 up-regulation. Other lysosomal inhibitors, including monensin and nigericin, also up-regulated DR5 and sensitized TRAIL-mediated apoptosis PMID: 26964637
  67. For osteosarcoma and acts through the TRAIL-DR-5 signaling pathway. PMID: 27461934
  68. MG132 may be a promising agent for sensitizing GBC-SD cells to TRAIL-induced apoptosis. PMID: 27277541
  69. No statistically significant difference was found in TRAIL mRNA expression between multiple sclerosis patients and controls. PMID: 27472871
  70. Study showed that TRAIL and caspase-8 expression decreased in human osteosarcoma, resulting in increased cell proliferation, and reduced cell apoptosis suggesting they play important roles in the occurrence, development, and prognosis of osteosarcoma. PMID: 28002586
  71. OPG/TRAIL ratio can be proposed as a predictor of cardiovascular dysfunction and mortality. PMID: 27128817
  72. Data shwo that tumor size independently correlates to circulating -related apoptosis-inducing ligand (TRAIL) levels. PMID: 27067438
  73. HUMSCs expressing ISZ-sTRAIL might be an efficient therapeutic approach against lung cancer and MCP-1/CCR2 axis is essential for the tumor tropism of HUMSCs PMID: 26733169
  74. Edelfosine also activated p38MAPK (MAPK14), and edelfosine-mediated rhTRAIL sensitization was partially regulated by a p38-mediated decrease in mitochondrial membrane potential. This study suggests a novel therapeutic strategy targeting gastric cancer cells by using the combination of edelfosine and TRAIL. PMID: 26615420
  75. Pro-survival effects by NF-kappaB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer, which may explain why up-regulated DR4 and DR5 in ovarian cancer are associated with poor prognosis and low survival ratio of the patients. PMID: 27780136
  76. the present study found that CAPE significantly enhanced TRAIL-mediated apoptosis in Hep3B carcinoma cells and suggested that CAPE has promising potential in chemoprevention of hepatocellular carcinomas. PMID: 27260301
  77. TRAIL may be related to susceptibility to hepatitis B. PMID: 27466296
  78. Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology.( PMID: 26935795
  79. AAV-sTRAIL combined with lanatoside C induced cell death in U87 glioma cells and patient-derived GBM neural spheres in culture and in vivo leading to an increased in overall mice survival. PMID: 26708508
  80. WIN-dependent increase in the level of SPARC plays a critical role in sensitizing osteosarcoma cells to TRAIL action PMID: 26698404
  81. RT-PCR demonstrated increased synthesis of TRAIL and its receptors in lesional vs. non-lesional skin. PMID: 25279491
  82. Smad2 enhances TRAIL-induced apoptosis in activated hepatic stellate cells, which facilitates the resolution of hepatic fibrosis PMID: 26802603
  83. NGF FLIPs TrkA onto the death TRAIL in neuroblastoma cells PMID: 26962689
  84. Demonstrate a unique approach to overcome TRAIL-based therapy drawbacks using sequential administration of a tumor-homing TRAIL sensitizer, doxorubicin, and long-acting TRAILPEG. PMID: 26381901
  85. Bcl-xL is responsible for TRAIL resistance in human pancreatic cancer cells. Bcl-2 family inhibitors could represent promising reagents to sensitize human pancreatic cancers to TRAIL. PMID: 26506422
  86. Study investigated the association between colorectal cancer and polymorphisms in TRAIL and DR4 gene in Pakistani patients; TRAIL gene 1595 C>T genotypes percentage in colorectal cancer patients was statistically non-significant; for DR4 A1322G, homozygous GG genotype was 36% in the patients and in controls: there was statistically insignificant difference (p> 0.05). PMID: 26518902
  87. ISG15 is elevated in viremic HIV-1 patients and is associated with high TRAIL and IDO levels. PMID: 26563749
  88. Our findings suggested that GA induces apoptosis via the downregulation of cFLIPL and sensitized TRAIL-mediated apoptosis in Caki cells. PMID: 26648023
  89. Circulating TRAIL and DR5 increased in COPD patients and were associated with lung function and systemic inflammation in COPD. PMID: 26609227
  90. TRAIL genetic polymorphisms do not contribute, but DR4 polymorphisms may contribute to susceptibility to head and neck cancer in Pakistani population. PMID: 26718429
  91. The angiogenic effect of TRAIL on human microvascular endothelial cell-1 cells is downstream of fibroblast growth factor-2, involving NOX4 and nitric oxide signaling. PMID: 26572549
  92. OPG and TRAIL are associated with the underlying cardiovascular damage in atrial fibrillation, but their balance is modulated by the fact of sinus rhythm restoration. PMID: 26504794
  93. Report TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells. PMID: 26320191
  94. Authors screened for genes differentially expressed in RAFLS sensitive and resistant to TRAIL-induced apoptosis. The sensitivity of RAFLS was defined based on the percentage of TRAIL-induced apoptosis: 0-10% for resistant and >25% for sensitive RAFLS. PMID: 26247836
  95. The structure of death receptor 4 (DR4) in complex with TNF-related apoptosis-inducing ligand (TRAIL) has been determined at 3 A resolution and compared with those of previously determined DR5-TRAIL complexes. PMID: 26457518
  96. Report alpha-mangostin functions as a sensitizer of TRAIL-induced apoptosis and may thus serve as a possible adjuvant compound for cytokine therapy to conquer TRAIL-resistance. PMID: 26304927
  97. DcRs regulate TRAIL sensitivity at a supracellular level PMID: 26050621
  98. Seminal TRAIL may have a potential role in varicocele-associated male infertility through its negative effect on sperm motility and morphology. PMID: 25351208
  99. Combination treatment of Huh7 cells with TRAIL and Taraxacum officinale resulted in TRAIL-induced apoptosis mediated through inhibition of the MKK7-TIPRL interaction and subsequent activation of MKK7-JNK phosphorylation. PMID: 25647515
  100. Valproic acid sensitized TRAIL-resistant papillary thyroid carcinoma cells to apoptotic cell death through involvement of Nrf2 and Bcl-xL. PMID: 26721202

Show More

Hide All

Subcellular Location Membrane, Single-pass type II membrane protein
Protein Families Tumor necrosis factor family
Tissue Specificity Widespread; most predominant in spleen, lung and prostate.
Database Links

HGNC: 11925

OMIM: 603598

KEGG: hsa:8743

STRING: 9606.ENSP00000241261

UniGene: Hs.478275

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1